Elotuzumab (HuLuc63)

What is Elotuzumab?

Elotuzumab, also known as HuLuc63, is a monoclonal antibody being developed by Facet Biotech (a spin-off company of PDL BioPharma, Inc) in collaboration with Bristol-Myers Squibb. Elotuzumab binds to CS1, a cell surface protein that is highly expressed on myeloma cells but minimally expressed on normal cells. This agent is given as an intravenous infusion.

What do we know about Elotuzumab’s activity in myeloma?

In the laboratory, elotuzumab has been shown to kill myeloma cells, including those that are resistant to other anti-myeloma therapies. When elotuzumab is combined with other anti-myeloma therapies, the activities of both are enhanced (ie, they act synergistically). Elotuzumab also caused tumor regression in a mouse model of myeloma.

How is Elotuzumab currently being studied in myeloma?

Elotuzumab is currently being evaluated in two clinical trials in myeloma being facilitated by the Multiple Myeloma Research Consortium (MMRC):

  • A Phase I/II trial in combination with Velcade® (bortezomib) in patients who have received one to three prior therapies
  • A Phase I trial in combination with Revlimid® (lenalidomide) and dexamethasone in patients with relapsed myeloma

Encouraging preliminary data from both studies were presented at the International Myeloma Workshop in Washington, D.C. in February, 2009 and no unexpected safety concerns were reported.

Click here to go to the MMRF Clinical Trial Matching Service.